human recombined insulin

PreclinicalSmall molecule

KK. Marcinkowski University of Medical Sciences

human recombined insulin is one of 32 small molecule programs targeting Gestational Diabetes. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gestational DiabetesActive, not recruiting

Gestational DiabetesPreclinical

Active, not recruiting

Competition

Competitive Landscape

57 competitors in Gestational Diabetes

#DrugCompanyPhaseTrials

Glucophage

EMD Serono

Approved

28 2

Diabeta

Pfizer

Approved

8 3

Byetta

AstraZeneca

Approved

2 4

Victoza

Novo Nordisk

Approved

1 5

Folvite

Eli Lilly

Approved

1 6

Calciferol

Alnylam Pharmaceuticals

Actigall

Insulin 320

4 9

Ursodeoxycholic Acid

Daewoong Pharmaceutical Co. LTD.

Approved

1 10

Precose

Bayer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Gestational Diabetes1 trial

Metformin in Gestational Diabetes Mellitus

Completed·KK. Marcinkowski University of Medical Sciences·N/A·NCT00681460·78 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for human recombined insulin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — human recombined insulin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for human recombined insulin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — K. Marcinkowski University of Medical Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: KK. Marcinkowski University of Medical Sciences

human recombined insulin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Gestational Diabetes1 trial

References

Drug Info

Quick Facts

Related News